00:49 , Aug 17, 2019 |  BioCentury  |  Emerging Company Profile

Impact casting a wide synthetic lethality net

After laying the foundation with its PARP inhibitor, Impact plans to build a comprehensive synthetic lethality pipeline across known DNA damage repair targets and new ones outside of DDR to address a wider range of...
12:56 , Apr 30, 2019 |  BC Innovations  |  Distillery Therapeutics

Small molecule FTO inhibitor to treat AML

DISEASE CATEGORY: Cancer INDICATION: Acute myelogenous leukemia (AML) Cell culture and mouse studies identified a benzohydroxamic acid-based FTO inhibitor that could help treat AML. Chemical synthesis and optimization of meclofenamic acid, a previously reported FTO...
17:29 , Apr 22, 2019 |  BC Innovations  |  Distillery Techniques

Bacterial recA-based CRISPR system for high-efficiency gene editing

TECHNIQUES CATEGORY: Drug platforms TECHNOLOGY: Gene therapy A CRISPR-based gene editing system utilizing bacterial recA could correct disease-causing point mutations with greater efficiency than standard CRISPR-based systems. The system consists of a corrected single-strand DNA...
14:41 , Mar 7, 2019 |  BC Innovations  |  Translation in Brief

Blocking B cell vesicles to enhance chemotherapy

Blocking extracellular vesicles derived from B cells could offer a new therapeutic avenue to enhance the efficacy of chemotherapy for cancer, according to a Zhejiang University study. Chemotherapy reduces antitumor immunity by inducing systemic immunosuppression....
15:49 , Feb 28, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer Patient sample and mouse studies suggest inhibiting RAB27A-dependent formation of CD19-positive extracellular vesicles could enhance the efficacy of chemotherapy for colorectal cancer. In serum samples from colorectal cancer patients, levels of CD19-positive...
19:08 , Aug 3, 2018 |  BC Week In Review  |  Financial News

Impact raises $30M series C

Impact Therapeutics Inc. (Nanjing, China) raised $30 million in an untranched series C round led by new investor Decheng Capital. Existing investor Lilly Asia Ventures also participated. Impact is developing IMP4297, a PARP-1 inhibitor that...
19:50 , Aug 2, 2018 |  BC Extra  |  Financial News

Impact raises $30M series C

Impact Therapeutics Inc. (Nanjing, China) raised $30 million in an untranched series C round led by new investor Decheng Capital. Existing investor Lilly Asia Ventures also participated. Impact is developing IMP4297, a PARP-1 inhibitor that...
17:49 , Jun 28, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Staphylococcus Cell culture studies identified three cadmium-based supramolecule coordination complexes (SCCs) that could help treat methicillin-resistant Staphylococcus aureus (MRSA) infection. The three SCCs consist of hexagonal-shaped rings that incorporate 12, 18 or 24 cadmium...
22:49 , Apr 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Bacterial infection Cell culture studies identified a dimeric lysine alkylamide-based compound that could help treat bacterial infection. Chemical synthesis and testing in bacterial cultures of dimeric lysine alkylamide analogs yielded a compound that inhibited...
16:58 , Mar 22, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer Patient sample, cell culture and mouse studies suggest inhibiting RIPK1 or MCU could help treat colorectal cancer. In patient samples, tumor levels of RIPK1 and MCU were higher than in adjacent normal...